Introduction
============

Retinitis pigmentosa (RP) is a diverse group of disorders characterized by progressive retinal dysfunction, and caused by mutations in at least 50 genes ([RetNet](http://www.sph.uth.tmc.edu/Retnet/) accessed April 1, 2014). It has been estimated that about 40--50% of disease remains unaccounted for by screening of known genes, which suggests many more causative genes await identification \[[@r1],[@r2]\]. Clinically, RP presents with night blindness and peripheral visual field constriction, with later central visual loss. At the cellular level, photoreceptor cell death occurs over time with the initial loss of rods, followed by cones at later stages of disease \[[@r2],[@r3]\]. The phenotype, including onset and progression, shows considerable variability, even within families \[[@r4],[@r5]\].

X-linked RP (XLRP) accounts for 5--20% of RP \[[@r2]\]. Three disease-causing genes have been identified to date: retinitis pigmentosa GTPase regulator (*RPGR*; OMIM [312610](http://www.ncbi.nlm.nih.gov/omim/?term=312610)) \[[@r6]\], retinitis pigmentosa 2 (*RP2*; OMIM [312600](http://www.ncbi.nlm.nih.gov/omim/?term=312600)) \[[@r7]\], and oral-facial-digital syndrome type 1 (*OFD1*; OMIM [300170](http://www.ncbi.nlm.nih.gov/omim/?term=300170)) gene \[[@r8]\].

Mutations within *RPGR* cause approximately 80% of all XLRP, the highest rate of any RP locus identified to date \[[@r2],[@r9]\]. The *RPGR* gene has 23 exons, including the alternatively spliced exons 9a, ORF15, 15a, and 15b \[[@r9],[@r10]\]. Most mutations are located in ORF15, which is predominantly present in retinal transcripts. *RPGR* participates in intracellular protein trafficking through the connecting cilia of the photoreceptor cells \[[@r9]-[@r11]\].

The phenotype of XLRP associated with *RPGR* is considered one of the most severe, with an early onset in men, usually in the first or second decade, leading to significant visual impairment by the fourth decade. In female carriers, the disease is typically milder, presenting with a tapetal-like reflex or peripheral retinal pigmentary deposits, and can be asymptomatic \[[@r4],[@r5],[@r12]\].

Because of the anticipated introduction of gene therapy approaches, it is important to document specific genotype-phenotype correlations in detail. Herein we report the unusual severe phenotype associated with a c.2543del ORF15 *RPGR* mutation with profound visual loss in female carriers.

Methods
=======

A large five-generation family of Caucasian Czech background with RP was studied. Graphical presentation of the family tree was done using HaploPainter software \[[@r13]\] ([Haplopainter](http://haplopainter.sourceforge.net/)). The research followed the tenets of the Declaration of Helsinki, and informed consent approved by the local ethics committee was obtained from each participant before the study.

Molecular genetic analysis
--------------------------

Blood samples (6 ml) were taken from participating family members. DNA was extracted from peripheral blood leucocytes using the Nucleon Genomic DNA Extraction Kit BACC3 according to the manufacturer's instructions (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Genotyping microarray version 2.0 (Asper, Tartu, Estonia) testing was used for initial screening in the proband. This array simultaneously analyzes 370 known mutations and polymorphisms within 15 genes known to be implicated in autosomal dominant RP. Next, ORF15 screening of the *RPGR* gene (reference sequence [NM_001034853.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_001034853.1)) was performed at the National Genetic Reference Laboratory in Manchester, UK, as previously described \[[@r9]\].

Description of nucleotide and protein changes was as recommended by the Human Genome Variation Society \[[@r14],[@r15]\] ([HGVS](http://www.hgvs.org)).

Clinical assessment
-------------------

Clinical examination included best corrected visual acuity (BCVA) measurements using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, slit-lamp evaluation including funduscopy, Goldmann intraocular pressure measurements, the Lanthony 15-hue desaturated test, and static automatic perimetry (M-700, Medmont International, Vermont, Australia, and Peristat 433, G. Rodenstock Instruments GmbH, Ottobrunn-Riemerling, Germany). Spectral domain optical coherence tomography (SD-OCT) and peripapillary retinal nerve fiber layer (RNFL) thickness measurements were performed using two spectral-domain devices (Spectral OCT/SLO, OTI Ophthalmic Technologies Inc., Toronto, Canada, and Spectralis, Heidelberg Engineering GmbH, Heidelberg, Germany) allowing in vivo retinal cross sectioning with an axial resolution of 6 µm. RNFL thickness was acquired by circular scans 3.46 mm in diameter around the optic nerve in the temporal (316°--45°), superior (46°--135°), nasal (136°--225°), and inferior (226°--315°) quadrants. Choroidal thickness was measured manually on horizontal foveal SD-OCT scans.

The inner segment ellipsoid (ISe) band within the central 3.0 mm on the horizontal mid-line scan (gray-scale image) of the fovea was classified into three categories: absent; partially intact, i.e., a distinct line within the central 1.0 mm; and intact. Foveal minimum thickness, i.e., the distance between the signal transition at the vitreoretinal interface and the RPE layer in an area of the central 1.0 mm, was measured manually on horizontal SD-OCT scans. Family members refused to undergo electroretinography, since individual II:5 ([Figure 1](#f1){ref-type="fig"}) was convinced that she had lost her residual light projection immediately after this examination in the past.

![Pedigree of a family with retinitis pigmentosa associated with a c.2543del mutation in *RPGR* ORF15. Clinically examined individuals are indicated with an asterisk. All family members with bone spicules indicative of typical retinitis pigmentosa (RP) are shown shaded in black as affected. Individuals with myopia (−3.0 to −15.0 diopter sphere) but no pigmentary retinopathy are shown shaded in gray. Individuals III:4, III:9, IV:2, IV:4, and IV:11 were positive for the disease-causing mutation, whereas III:3 and IV:12 were negative. For individuals II:5, III:1, III:6, III:7, III:11, IV:1, IV:3, IV:6, IV:8, IV:15, and V:1, no DNA was available for laboratory investigation.](mv-v20-1307-f1){#f1}

Results
=======

The pedigree is shown in [Figure 1](#f1){ref-type="fig"}. No pathogenic change was detected with genotyping microarray analysis of known mutations in 15 genes implicated in dominant RP. Next, an X-linked mode of inheritance was considered since there was no male-to-male transmission in the family ([Figure 1](#f1){ref-type="fig"}) and several women with and without bone spicules had high myopia. Myopia has been reported in patients with *RP2* and *RPGR* mutations, particularly in those who harbor ORF15 pathogenic changes \[[@r4],[@r5],[@r12],[@r16]\].

Sequence analysis of the *RPGR* gene in the proband (III:4) identified a c.2543del; p.(Glu848Glyfs\*241) mutation in ORF15 of *RPGR*. The same sequence variant was also present in two other family members with RP (III:9 and IV:2): one woman with high myopia and no pigmentary retinopathy (IV:11) and one woman who appeared clinically normal (IV:4). Two clinically unaffected first-degree relatives (III:3 and IV:12) did not harbor c.2543del in *RPGR* ([Figure 1](#f1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). In summary, the mutation segregated with disease in the pedigree.

###### Serial clinical observations in individuals from a family with retinitis pigmentosa caused by a c.2543del in *RPGR* ORF15.

  **Individual/gender**   **Age (yrs)**   **BCVA**   **Subjective refraction (DS/DC)**   **Pigmentary deposits**   **Color Vision Deficiencies**   **Mutation**                                                                                 
  ----------------------- --------------- ---------- ----------------------------------- ------------------------- ------------------------------- -------------- --------------------------------------------- --------------- --------------- --------------------------------
  II:5/F                  67              LP         HM                                  −15.0                     −15.0                           Y              Y                                                                             Not tested -- obligate carrier
  72                      TB              TB         UA                                  UA                        Y                               Y                                                                                            
  III:1/F                 58              0.63       0.63                                −6.0/-2.5                 −4.0/-1.5                       Y              Y                                                                             Not tested -- obligate carrier
  64                      0.2             0.64       −6.0/-2.5                           −5.0/-1.0                 Y                               Y              Moderate tritan                               Mild protan                     
  III:3/M                 52              1.0        1.0                                 UA                        UA                              N              N                                                                             Not found
  III:4/F                 47              0.25       0.4                                 −15.0/-0.25               −14.0/-0.75                     Y              Y                                                                             Present
  54                      0.2             0.32       −11.5                               −11.5                     Y                               Y              Mild tritan                                   Mild protan                     
  58                      0.2             0.4        −11.5                               −11.5                     Y                               Y                                                                                            
  III:6/M                 48              0.16       0.16                                −6.5/-1.5                 −6.0/-1.5                       Y              Y                                                                             Not tested
  III:7/F                 53              0.5        0.63                                −11.0/-1.25               −8.0/-2.0                       N              N                                                                             Not tested
  III:9/F                 44              0.04       1.0                                 −11.0/-2.0                −4.0/-2.0                       Y              N                                                                             Present
  50                      0.03            1.0        −11.0/-2.0                          −4.5/-2.0                 Y                               Y              Impossible to test due to visual impairment   Mild tritan                     
  III:11/F                41              1.0        1.0                                 None                      None                            N              N                                                                             Not tested
  IV:1/M                  42              0.25       0.25                                −3.0/-2.0                 −3.0/-2.0                       Y              Y                                             Severe protan   Severe protan   Not tested
  IV:2/M                  32              0.4        0.5                                 −8.5/-3.5                 −9.0/-1.0                       Y              Y                                                                             Present
  38                      0.32            0.4        −9.5/-3.0                           −9.5/-3.5                 Y                               Y              Moderate tritan                               Mild protan                     
  IV:3/M                  23              0.5        0.5                                 −11.0                     −11.0/-1.0                      Y              Y                                                                             Not tested
  27                      0.4             0.4        −11.0                               −11.0                     Y                               Y                                                                                            
  30                      0.16            0.32       −11.0                               −11.0                     Y                               Y              Moderate protan                               Severe protan                   
  IV:4/F                  25              1.0        1.0                                 None                      None                            N              N                                                                             Present
  29                      1.0             1.0        None                                None                      N                               N              None                                          None                            
  32                      1.0             1.0        None                                None                      N                               N                                                                                            
  IV:6/M                  14              0.8        0.8                                 −3.25/-1.75               −2.75/-1.5                      N              N                                                                             Not tested
  19                      0.8             0.8        −5.5/-1.0                           −5.0                      Y                               Y              None                                          None                            
  IV:8/F                  22              0.32       0.32                                −10.5/-3.5                −13.5/-1.75                     N              N                                                                             Not tested
  IV:11/F                 25              0.63       0.5                                 −4.5/-3.0                 −10.0/-2.5                      N              N                                                                             Present
  IV:12/M                 37              1.0        1.0                                 UA                        UA                              N              N                                                                             Not found
  IV:15/M                 11              1.0        1.0                                 None                      None                            N              N                                                                             Not tested
  V:1/M                   4               UA         UA                                  −2.5/-2.5                 −2.5/-2.5                       N              N                                                                             Not tested
                          6.5             1.0        0.5                                 −2.5/-2.5                 −2.5/-2.5                       N              N                                                                             
                          10              0.5        0.5                                 −3.0/-2.5                 −3.0/-3.0                       N              N                                                                             

BCVA: best corrected visual acuity, DS: diopter sphere, DC: diopter cylinder, F: female, HM: hand movement, M: male, LE: left eye, RE: right eye, N: No, Y: yes, yrs: years, TB: total blindness, UA: unavailable data. Color vision was tested using Lanthony 15-Hue Desaturated Test.

Eighteen family members (nine women and nine men) were clinically examined. In some subjects, serial observations were performed over a period of up to 11 years. A summary of their clinical findings is provided in [Table 1](#t1){ref-type="table"}. No systemic or sensory disorder was found to cosegregate with RP in the family.

Female patients I:1, II:1, II:3, and II:5 were reported to become "totally blind" in their 60s and 70s. Bilateral no perception of light was confirmed in patient II:5. There was a variable onset of nyctalopia. Female patients II:5 and III:9 noticed difficulties in dim light in childhood, III:1 at the age of 30 years, and III:4 had attended a school for visually handicapped children and had reported impaired orientation during the day and night since childhood. With one exception (IV:4), all women had reduced BCVA, high myopia, and astigmatism in at least one eye. Signs of RP (pigmentary retinopathy, attenuated vessels, optic disc pallor, and posterior subcapsular cataracts) in at least one eye were found in female individuals II:5, III:1, III:4, and III:9. Macular atrophy was also common ([Table 1](#t1){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}, [Figure 3](#f3){ref-type="fig"}). White dots were noted in the fundus periphery of the right eye of individual III:9; her left eye could not be adequately examined since the patient refused dilation ([Figure 2C](#f2){ref-type="fig"}). None of the examined women had evidence of a tapetal reflex.

![Spectrum of fundus finding in two women and one man with retinitis pigmentosa caused by a c.2543del *RPGR* ORF15 mutation. **A**: Composite fundus photography of the right eye of female III:4 at the age of 54 years. **B**: Composite fundus photography of the right eye of female III:9 at the age of 50 years; note the chorioretinal degeneration at the macula and in the periphery with intraretinal asymmetric involvement. **C**: Red-free imaging enhancing peripheral white dots in the upper nasal quadrant of the right eye of female III:9. **D**, **E**: Fundus photographs of male IV:6 aged 19; note the relatively normal appearing macula and pigment clumps in the mid-periphery.](mv-v20-1307-f2){#f2}

![Horizontal optical coherence tomography images cross sectioning the fovea in the right eyes of affected men and women who carry a c.2543del mutation in *RPGR* ORF15. Choroidal thickness is indicated with a red bar. **A**: Normal retinal architecture in a 40-year-old control individual (enhanced depth imaging). **B**: Chorioretinal thinning, missing foveal depression, scar formation, and epiretinal membrane (arrow) in female III:1 at the age of 64 years. **C**: Chorioretinal thinning, missing foveal depression, and vitreomacular traction associated with foveal elevation in female III:4 at the age of 54 years. **D**: Chorioretinal thinning, myopic foveoschisis, and posterior staphyloma in female III:9 at the age of 50 years. **E**: Chorioretinal thinning and focal retinal thickening in male IV:1 at the age of 42 years. **F**: Chorioretinal thinning and myopic posterior staphyloma in male IV:2 at the age of 38 years. **G**: Chorioretinal thinning, macular hole, and myopic posterior staphyloma in male IV:3 at the age of 30 years. **H**: Normal retinal and choroidal architecture in female IV:4 at the age of 32 years (enhanced depth imaging). **I**: Choroidal thinning and normal retinal architecture in male IV:6 at the age of 19 years.](mv-v20-1307-f3){#f3}

All affected male individuals, III:6, IV:1, IV:2, and IV:3 (except IV:6 aged 19 years who was asymptomatic), reported onset of nyctalopia between 10 and 20 years of age and refractive errors since early childhood. All had typical ocular features of RP (including IV:6; [Figure 2](#f2){ref-type="fig"}). Mild to high myopia with astigmatism and macular atrophy was also present ([Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}, [Figure 3](#f3){ref-type="fig"}). Serial examination with static perimetry demonstrated progressive visual field constriction ([Figure 4](#f4){ref-type="fig"}). Disruption of the macular architecture including the absence of the ISe band together with retinal thinning was documented with SD-OCT in the majority of the subjects ([Table 2](#t2){ref-type="table"}, [Figure 3](#f3){ref-type="fig"}).

###### Spectral domain optical coherence tomography findings in individuals with a c.2543del mutation in *RPGR* ORF15.

  **Individual/gender**   **Age (yrs)**   **ISe**   **Foveal thickness (µm)**   **Choroidal thickness (µm)**   **RNFL thickness (µm)**                        
  ----------------------- --------------- --------- --------------------------- ------------------------------ ------------------------- ----- ----- -------- --------
  III:1/F                 64              A         I                           395 (epiretinal membrane)      195                       90    75    TQ 107   TQ 151
  III:4/F                 54              A         P                           140                            230                       30    50    UA       UA
  III:9/F                 50              P         P                           220                            200                       130   150   TQ 132   TQ 96
  IV:1/M                  42              P         P                           190 (epiretinal membrane)      150                       120   110   TQ 162   TQ 172
  IV:2/M                  38              A         A                           120                            130                       40    40    TQ 129   TQ 171
  IV:3/M                  30              A         P                           Macular hole                   130                       80    35    TQ 133   TQ 101
  IV:4/F                  32              I         I                           170                            165                       600   590   Normal   Normal
  IV:6/M                  19              I         I                           165                            165                       135   110   Normal   Normal

A: absent, F: female, I: intact, ISe: Inner segment ellipsoid band, LE: left eye, M: male, P: partially intact, RE: right eye, RNFL: retinal nerve fiber layer, TQ: temporal quadrant, UA: unavailable data. Minimal foveal thickness shown does not include pathological epiretinal membrane. Choroidal thickness was measured subfoveally. Exact values of RNFL thickness are shown for abnormal quadrants. Normal range of foveal thickness 261.31 ± 17.67 μm \[[@r33]\]. Normal range of choroidal thickness 336.60 ± 70.42 μm \[[@r27]\]. Normal range of RNFL thickness 79.5 ± 15.3 μm \[[@r34]\].

![Serial observations of disease progression on automated visual field for individuals with a c.2543del *RPGR* ORF15 mutation. Visual field scans (showing 50° nasal and temporal to fixation) of the right and left eyes of female III:4 at the age of 47 (**A**) and 58 (**B**) years; the right and left eyes of female III:1 at the age of 58 (**C**) and 64 (**D**) years; the right and left eyes of female III:9 at the age of 44 (**E**) and 50 (**F**) years; the right and left eyes of female IV:4 at the age of 25 (**G**) and 29 (**H**) years; the right and left eyes of male IV:3 at the age of 23 (**I**) and 30 (**J**) years; the right and left eyes of male IV:6 at the age of 14 (**K**) and 19 (**L**) years; the right and left eyes of male IV:2 at the age of 32 (**M**) and 38 (**N**) years; the right and left eyes of male IV:1 at the age of 42 (**O**) years. Static perimetry results are shown as 12-level gray scales of sensitivity loss. Black areas indicate no detection of stimuli. Physiologic blind spot is shown as a black circle at 12° in the temporal field.](mv-v20-1307-f4){#f4}

All individuals with pigmentary retinopathy and family members who harbored the c.2543del mutation in *RPGR*, except female carrier IV:4, had abnormal subfoveal choroidal thickness ([Table 2](#t2){ref-type="table"}). In addition, a full-thickness macular hole (minimum diameter 460 µm, base diameter 890 µm) was present in the right eye of individual IV:3 ([Figure 3G](#f3){ref-type="fig"}). In severely affected men, the RNFL thickness was increased in the temporal quadrants ([Table 2](#t2){ref-type="table"}).

Discussion
==========

Reports of large families with XLRP mimicking autosomal dominant inheritance are uncommon \[[@r5],[@r17]-[@r19]\]. Herein we describe a Czech family with RP with severe retinal degeneration in women carrying a c.2543del mutation (p.Glu848Glyfs\*241) in *RPGR* ORF15. This sequence variant was previously found in one man from Central Europe, but no phenotypic description was provided \[[@r20]\]. RP is genetically heterogeneous. This is only the second report on the molecular genetic cause of RP from the Czech Republic \[[@r21]\].

It has been previously shown that in families with RP considered to be most likely autosomal dominant without male-to-male transmission and in severely affected sporadic men, X-linked inheritance should be considered \[[@r22],[@r23]\]. Screening for mutations in *RP2* and *RPGR* in a recent study revealed that 8.5% (22 out of 258) of such pedigrees were attributed to mutations in these genes and that they were in fact X-linked \[[@r22]\]. Initial evaluation of our pedigree with individuals affected in four consecutive generations including several severely affected women favored autosomal dominant inheritance. Failure to identify a disease-causing mutation using a microarray for detecting known mutations implicated in autosomal dominant RP and significant myopic refractive errors previously reported in men and women from families with XLRP \[[@r4],[@r5],[@r12],[@r16]\] led us to screen *RPGR*.

The disease severity varied among the affected women in our family. In addition, we observed inter-ocular asymmetry, in contrast to the symmetry observed in the men. Myopia and astigmatism were present in all but one carrier and in all affected men. Refractive errors were also documented in three other women without signs of typical RP. One was found to be a carrier for the c.2543del mutation in *RPGR* ORF15, while the other two were not available for molecular genetic analysis.

Although the structure of the pedigree presented here and known phenotypic variability in XLRP expression \[[@r4],[@r5],[@r12],[@r16],[@r24]\] make it difficult to compare the phenotype between men and women of the same age, comparison of three siblings in generations III and IV corroborates that women show later onset and less severe loss of visual field when compared to similarly aged men \[[@r17]\]. Nevertheless, women in generation II had no perception of light bilaterally, which is unusually severe. The mechanism(s) underlying variable disease expression in women as well as the factors that contribute to inter-individual phenotypic heterogeneity remain elusive, but include skewed inactivation in women and other genetic modifiers \[[@r5],[@r12],[@r25]\].

To aid the clinical characterization of the severe phenotype in women, we performed detailed SD-OCT. A range of findings from normally appearing retinal architecture to gross abnormalities was observed. Marked structural disruption precluded reliable distinction between retinal layers. In one eye of a 30-year-old man, we documented a macular hole. Macular hole is an uncommon finding in RP. Hagiwara et al. (2011) found only three patients out of 323 (three eyes out of 622) with this pathology on OCT imaging \[[@r26]\]. Recently, several studies indicated that changes in choroidal morphology and thinning represent a distinct feature in RP \[[@r27],[@r28]\]. Our study not only confirms these findings but is also the first one that provides correlation with the genotype. Since we also observed choroidal thinning in female carriers with no bone spicule-like formation or tapetal reflex, choroidal evaluation may be a useful non-invasive, readily available assessment for carrier status. However, since decreased choroidal thickness can also be observed in myopic eyes \[[@r29]\] and myopia was also present in the women examined in our study, the broad relevance and resulting implications of this parameter in RP diagnosis and evaluation of progression warrant further investigation.

Increased thickness, as well as decreased thickness of the RNFL in RP, has been reported previously \[[@r30]-[@r32]\], however, not in molecularly confirmed RP. It has been suggested that increased RNFL thickness may be associated with cone system abnormality \[[@r30],[@r31]\]. Clinical findings in our patients support this observation. Nine out of 10 eyes observed to have increased RNFL thickness also had abnormalities of the foveal architecture, including an absent or markedly disrupted ISe band; in the remaining eye with an intact ISe band, the 15-hue test revealed a mild color vision defect.

In conclusion, in pedigrees where male-to-male transmission is absent, X-linked inheritance should be considered despite the presence of severe signs of retinal degeneration in women. Moderate and high myopia in affected individuals of both sexes, as well as ocular asymmetry in women, may also be suggestive of X-linked inheritance. Evaluation of choroidal thickness may prove to be a valuable readily available method for clinically identifying female carriers.
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